Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (rod photoreceptor cells) | 0.10 |
| chemistry Open Targets | reachable by antibody: fe 203799, teduglutide, elsiglutide | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 183 | 0.85 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 16889
Sealed predictions
- GLP2R in dopamine neurons, braak+0.16 (p 0.685) → -0.36 (p 0.341)receipt 16897
Swarm cases
receipt 16897: GLP2R in dopamine neurons, braak
- power
- full sample -0.15 (p 0.544, n 18), 95% CI -0.58 to +0.34. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.15 (p 0.544, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.37 (p 0.135, n 18). could be the mix.
- skeptic
- leave-one-out range -0.29 to -0.05, sign flips 0; without severely affected donors -0.15 (p 0.544, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GLP2R in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts